Alert Communication: Sodium valproate (Epilim) use in people who can father children

+Undoctored

Alert Communication: Sodium valproate (Epilim) use in people who can father children

Medsafe
1 minute to Read
PreviousNext
Undoctored

Sodium valproate (Epilim) use in people who can father children: important new safety information

Medsafe is highlighting new information that suggests a potential increased risk of neurodevelopmental disorders in children whose fathers were treated with sodium valproate (Epilim) at the time of the child’s conception.

Advice for consumers

  • Keep taking your Epilim/sodium valproate as prescribed by your doctor.
  • If you father a child while taking Epilim/sodium valproate, it is possible the child may have impaired mental and/or motor development problems.
  • Use effective contraception if you are starting or continuing on Epilim/sodium valproate treatment
  • If you are able to father children, speak with your doctor about the potential risks of taking Epilim/sodium valproate during conception, and your options if you wish to start a family.

Information for healthcare professionals

  • The Epilim data sheet and CMI have been updated to include new safety information relating to use in males of reproductive potential.
  • Use of sodium valproate at the time of conception by people who are able to father children has been linked to a potential increased risk of neurodevelopmental disorders in children compared to those who took lamotrigine/levetiracetam.
  • Inform patients of this potential risk and consider alternative treatment options for those wishing to father a child.
  • Discuss the need for effective contraception when starting sodium valproate and periodically throughout treatment.
  • The company has produced a guide which should be provided to all male patients of reproductive potential using sodium valproate.

Read the alert communication for more information.

 

Missing out on our email newsletters? Sign up here:

 

You can unsubscribe at any time by clicking the link in the footer of our emails. For information about our privacy practices, please see our Privacy Statement.